## 10-Hydroxygambogic Acid: A Promising Anti-Cancer Agent
10-Hydroxygambogic acid (10-HGA) is a natural compound extracted from the resin of the **garcinia hanburyi** tree, also known as **gamboge**. It's a **highly potent and selective anti-cancer agent** with significant potential in research.
**Here's what makes 10-HGA important for research:**
**1. Anti-Cancer Properties:**
* **Multiple Mechanisms of Action:** 10-HGA has shown remarkable activity against a wide range of cancer cell lines, including leukemia, lymphoma, lung, liver, colon, breast, and prostate cancers. It works through several pathways, including:
* **Induction of Apoptosis:** It triggers programmed cell death in cancer cells, effectively eliminating them.
* **Cell Cycle Arrest:** It inhibits the proliferation of cancer cells by halting the cell cycle at specific checkpoints.
* **Inhibition of Angiogenesis:** It prevents the formation of new blood vessels that supply nutrients to tumors, effectively starving them.
* **Anti-Metastatic Activity:** It can suppress the spread of cancer cells to other parts of the body.
* **Selectivity and Low Toxicity:** 10-HGA exhibits selective toxicity, targeting cancer cells more effectively than normal cells, thus minimizing side effects.
**2. Research Potential:**
* **Novel Drug Development:** 10-HGA is being investigated as a potential therapeutic agent for the treatment of various cancers. Researchers are actively exploring its potential to be formulated into effective and safe drug therapies.
* **Combination Therapy:** 10-HGA shows synergistic effects when combined with other anticancer agents, enhancing their efficacy and offering better therapeutic outcomes.
* **Understanding Cancer Biology:** 10-HGA's mechanisms of action provide valuable insights into the complex pathways involved in cancer development and progression. This knowledge can lead to the development of new, targeted cancer therapies.
**3. Ongoing Research:**
* **Clinical Trials:** Several clinical trials are currently underway to evaluate the safety and efficacy of 10-HGA in humans with various cancer types.
* **Preclinical Studies:** Extensive preclinical research continues to explore 10-HGA's potential as a cancer therapeutic, including its pharmacokinetics, pharmacodynamics, and potential toxicity.
**Despite its promising potential, further research is needed to fully understand 10-HGA's effects and its potential for clinical application.** However, the current research data strongly suggest that 10-HGA holds significant promise as a potential anti-cancer agent and warrants continued investigation.
10-hydroxygambogic acid: metabolite of gambogic acid; structure in first source
ID Source | ID |
---|---|
PubMed CID | 71450485 |
CHEMBL ID | 2205164 |
MeSH ID | M0547218 |
Synonym |
---|
10-hydroxygambogic acid |
CHEMBL2205164 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID716719 | Covalent binding affinity to human recombinant TRX-1 assessed as change in protein configuration at 0.1 mM by MALDITOF mass spectrometry | 2012 | Journal of natural products, Jun-22, Volume: 75, Issue:6 | Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain. |
AID1216616 | Drug level in PBS buffer treated with gambogic acid at 50 uM preincubated for 10 mins followed by NADPH addition measured after 1 hr by LC-DAD-MS/MS analysis in absence of liver microsomes | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition. |
AID1216628 | Retention time of the compound in Sprague-Dawley rat bile treated with gambogic acid at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition. |
AID1216637 | Drug level in rat liver microsomes assessed as CYP450-mediated compound formation treated with gambogic acid at 50 uM preincubated for 10 mins followed by NADPH addition measured after 1 hr by LC-DAD-MS/MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition. |
AID1216638 | Drug level in Sprague-Dawley rat feces treated with gambogic acid at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition. |
AID716718 | Covalent binding affinity to human recombinant TRX-2 assessed as change in protein configuration at 0.05 mM by MALDITOF mass spectrometry | 2012 | Journal of natural products, Jun-22, Volume: 75, Issue:6 | Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain. |
AID1216640 | Drug level in Sprague-Dawley rat plasma treated with gambogic acid at 4 mg/kg, iv measured over 4 hrs by LC-DAD-MS/MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |